FDA approves Roche’s kidney inflammation drug

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME

AbbVie's Rinvoq beats Humira in key arthritis trial

The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor

Cambrex to invest $120 million to expand API manufacturing in US

Expanding US operations to address the increased demand for API development and manufacturing

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi

With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL

Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program

Biocon Biologics and Civica launch private-label Insulin glargine

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million

Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio